Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
ABEO Stock Chart & Stats
$4.59
-$0.15(-2.50%)
At close: 4:00 PM EST
$4.59
-$0.15(-2.50%)
Day’s Range― - ―
52-Week Range$3.93 - $7.54
Previous CloseN/A
Volume71.38K
Average Volume (3M)2.25M
Market Cap
$242.78M
Enterprise Value$103.05M
Total Cash (Recent Filing)$207.46M
Total Debt (Recent Filing)$24.11M
Price to Earnings (P/E)3.8
Beta0.77
Next Earnings
Mar 23, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding54,191,360
10 Day Avg. Volume3,427,651
30 Day Avg. Volume2,252,647
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.19
Price to Sales (P/S)0.00
P/FCF Ratio-3.91
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue257.63
Enterprise Value/Gross Profit-106.90
Enterprise Value/Ebitda1.15
Forecast
1Y Price Target
$22.17Price Target Upside383.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.14
Revenue Forecast (FY)$27.00M
Bulls Say, Bears Say
Bulls Say
Demand And ReimbursementIncreasing patient demand and reimbursement progress increase confidence in FY26+ Zevaskyn estimates and management's ability to achieve sustainable profitability.
Financial Performance3Q25 GAAP net loss was better than consensus estimates, showing financial performance exceeding expectations.
Market AcceptanceZEVASKYN was approved in the U.S. for the treatment of recessive dystrophic epidermolysis bullosa, signaling broad and early market acceptance.
Bears Say
Commercial Launch DelayManagement's temporary pause on patient biopsy collection due to a performance issue sets back the commercial launch by ~3 months and decreases confidence in now-lower 4Q25 estimate.
Revenue PerformanceAbeona did not record any revenue in 3Q25, missing the estimate of $8.5M, because no patients were treated during the period.
Abeona Therapeutics News
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $3.93 and its highest was $7.54 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $242.78M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Mar 23, 2026 which is in 117 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.282 by $0.182.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.33.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 54,191,360 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.282. Following the earnings report the stock price went up 18.465%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in ABEO
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.17 (383.01% Upside)
$22.17 (383.01% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 841.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $279.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.24%
12-Months-Change
Fundamentals
Return on Equity
75.90%
Trailing 12-Months
Asset Growth
91.63%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
ABEO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive outlook for Abeona Therapeutics, with strong advancements in the commercial launch of ZivaSkin, expansion of treatment centers, and favorable market access. However, there were notable challenges, including delays in patient treatment and increased SG&A expenses. The company's financial position remains strong, and its pipeline shows promising advancements.View all ABEO earnings summariesABEO Stock 12 Month Forecast
Average Price Target
$22.17
▲(383.01% Upside)
Technical Analysis
Ownership Overview
5.63% Insiders
7.56% Mutual Funds
43.07% Other Institutional Investors
34.89% Public Companies and
Individual Investors